More from the Author

• Case | HBS Case Collection | July 2020

  Applying Data Science and Analytics at P&G

  Srikant M. Datar, Sarah Mehta and Paul Hamilton

  Set in December 2019, this case explores how P&G has applied data science and analytics to cut costs and improve outcomes across its business units. The case provides an overview of P&G’s approach to data management and governance, and reviews the challenges associated with changing long-established work processes within the company. It concludes by exploring four examples of how P&G has applied analytics to its businesses.

  Keywords: data science; analytics; Analysis; Information; Information Management; Information Types; Innovation and Invention; Strategy; Consumer Products Industry; United States; Ohio;

  Citation:

  Datar, Srikant M., Sarah Mehta, and Paul Hamilton. "Applying Data Science and Analytics at P&G." Harvard Business School Case 121-006, July 2020.  View Details

  CiteView DetailsEducators

  Related

• Working Paper | HBS Working Paper Series | 2020

  SSRIs and Non-SSRIs: Case Histories of Significant Medical Advances

  Amar Bhidé, Srikant M. Datar and Katherine Stebbins

  Prozac is widely hailed as “a breakthrough drug for depression.” In 2020, the World Health Organization (WHO) estimated that over 264 million people worldwide suffer from depression, and 800,000 die by suicide each year. In 2014, researchers calculated the economic impact of depression—in terms of lost productivity, absenteeism, and treatment costs—to be USD$63 billion per year in the United States alone. Depression’s toll on lives and livelihoods prompted the WHO to place Prozac on its list of essential medicines in 2009.

  Keywords: Health Care and Treatment; Technological Innovation; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Innovation and Invention; Governing Rules, Regulations, and Reforms;

  Citation:

  Bhidé, Amar, Srikant M. Datar, and Katherine Stebbins. "SSRIs and Non-SSRIs: Case Histories of Significant Medical Advances." Harvard Business School Working Paper, No. 20-135, July 2020.  View Details

  CiteView Details

  Related

• Working Paper | HBS Working Paper Series | 2020

  Tamoxifen: Case Histories of Significant Medical Advances

  Amar Bhidé, Srikant Datar and Katherine Stebbins

  Tamoxifen is considered a “gold standard” treatment for millions of breast cancer patients. In 1985, twelve years after Imperial Chemical Industries (ICI), had first introduced tamoxifen in the United Kingdom (UK), the World Health Organization (WHO) designated it an essential cancer drug. In 2003, V. Craig Jordan, a leading tamoxifen researcher, estimated that “over 400,000 women are alive…as a result of tamoxifen therapy.”

  Keywords: Health Care and Treatment; Technological Innovation; Innovation and Invention; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Governing Rules, Regulations, and Reforms;

  Citation:

  Bhidé, Amar, Srikant Datar, and Katherine Stebbins. "Tamoxifen: Case Histories of Significant Medical Advances." Harvard Business School Working Paper, No. 20-134, July 2020.  View Details

  CiteView Details

  Related